-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AvK8T1uprcYq2hzfHuVT+DqkQUqPvO9Duk4B+OStNwO0T2voQVpBD1LqU9FVLnlP qMMarGw8vcLg3nSB6nZ++g== 0001005477-96-000529.txt : 19961121 0001005477-96-000529.hdr.sgml : 19961121 ACCESSION NUMBER: 0001005477-96-000529 CONFORMED SUBMISSION TYPE: 10QSB/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19960930 FILED AS OF DATE: 19961119 SROS: NONE FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10QSB/A SEC ACT: 1934 Act SEC FILE NUMBER: 033-98478 FILM NUMBER: 96669085 BUSINESS ADDRESS: STREET 1: 142 CYPRESS POINT RD CITY: HALF MOON BAY STATE: CA ZIP: 94019 BUSINESS PHONE: 4157261327 MAIL ADDRESS: STREET 1: 142 CYPRESS POINT RD CITY: HALF MOON BAY STATE: CA ZIP: 94019 10QSB/A 1 AMENDED FORM 10-QSB ================================================================================ United States Securities and Exchange Commission Washington DC 20549 --------------------------------------------------------- Form 10-QSB/A --------------------------------------------------------- Quarterly Report under Section 13 of the Securities Exchange Act of 1934 For the Quarterly Period Ended Commission File No. 0-27282 September 30, 1996 Atlantic Pharmaceuticals, Inc. 142 Cypress Point Road Half Moon Bay, California 94019 Telephone (415)726-1327 Incorporated in Delaware IRS ID # 36-3898269 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days: Yes [x] No [ ] Transitional Small Business Disclosure Format Yes [ ] No [x] 2,913,720 shares of common stock, $.001 par value, were outstanding on September 30, 1996 ================================================================================
- -------------------------------------------------------------------------------------------------------------------- Assets September 30, 1996 December 31, 1995 ==================================================================================================================== (unaudited) Current assets: Cash and cash equivalents $ 3,245,129 5,044,632 Prepaid expenses 32,500 48,000 - -------------------------------------------------------------------------------------------------------------------- Total current assets 3,277,629 5,092,632 ==================================================================================================================== Furniture and equipment, net of accumulated depreciation of $61,973 and $26,728 at September 30,1996 and December 31, 1995, respectively 87,196 55,791 - -------------------------------------------------------------------------------------------------------------------- $ 3,364,825 5,148,423 ==================================================================================================================== Liabilities and Stockholders' Equity ==================================================================================================================== Current liabilities: Accrued expenses $ 290,292 800,383 Accrued interest -- 115,011 Demand notes payable -- 125,000 Note payable -- 75,000 - -------------------------------------------------------------------------------------------------------------------- Total current liabilities 290,292 1,115,394 ==================================================================================================================== Stockholders' equity Preferred stock, $.001 par value. Authorized 50,000,000 shares; none issued and outstanding -- -- Common stock $.001 par value. Authorized 80,000,000 shares; 2,913,720 and 2,663,720 shares issued and outstanding at September 30, 1996 and December 31, 1995, respectively 2,914 2,664 Common stock subscribed. 182 shares at September 30,1996 and December 31,1995 -- -- Additional paid -in capital 10,634,938 9,043,875 Deficit accumulated during development stage (7,452,377) (4,880,968) Deferred compensation (110,400) (132,000) ==================================================================================================================== 3,075,075 4,033,571 Less common stock subscriptions receivable (218) (218) Less treasury stock, at cost (324) (324) - -------------------------------------------------------------------------------------------------------------------- Total stockholders' equity 3,074,533 4,033,029 - -------------------------------------------------------------------------------------------------------------------- $ 3,364,825 5,148,423 ====================================================================================================================
See accompanying notes to consolidated financial statements. Page 1 Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf. Atlantic Pharmaceuticals, Inc. November 18, 1996 Jon D. Lindjord ------------------------------- Jon D. Lindjord Chief Executive Officer and President Shimshon Mizrachi ------------------------------- Shimshon Mizrachi Controller Principal Accounting and Financial Officer 2 -----END PRIVACY-ENHANCED MESSAGE-----